Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gliclazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.97 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gliclazide SCHEMBL16387 | 0.99 | ALDH1A1 (1.00) | ALDH1A1LMNAAKR1C3GAATP53 | |
| Gliclazide SCHEMBL291434 | 0.99 | ALDH1A1 (1.00) | ALDH1A1LMNAAKR1C3GAATP53 | |
| Gliclazide SCHEMBL1537023 | 0.99 | ALDH1A1 (1.00) | ALDH1A1LMNAAKR1C3GAATP53 | |
| Gliclazide SCHEMBL6344915 | 0.93 | ALDH1A1 (0.88) | ALDH1A1LMNAAKR1C3GAATP53 | |
| Gliclazide SCHEMBL30011556 | 0.92 | ALDH1A1 (0.86) | ALDH1A1LMNAAKR1C3GAATP53 | |
| Gliclazide SCHEMBL6679802 | 0.89 | ALDH1A1 (0.80) | ALDH1A1LMNAAKR1C3GAATP53 | |
| Gliclazide SCHEMBL1967443 | 0.87 | ALDH1A1 (0.77) | ALDH1A1LMNAAKR1C3GAATP53 | |
| SCHEMBL17309638 | 0.85 | ALDH1A1 (0.76) | ALDH1A1LMNAAKR1C3GAATP53 | |
| SCHEMBL17309632 | 0.84 | ALDH1A1 (0.74) | ALDH1A1LMNAAKR1C3GAATP53 | |
| Gliclazide SCHEMBL22069924 | 0.84 | ALDH1A1 (0.72) | ALDH1A1LMNAAKR1C3GAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190837-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-11891448-B2 | Glycated CD59 peptides, their preparation, and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-02-06 | — | — | US | disclosed |
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220162333-A1 | GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-05-26 | — | — | US | disclosed |
| EP-3939971-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-11161910-B2 | Glycated CD59 peptides, their preparation, and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210171495-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2021-06-10 | — | — | US | disclosed |
| EP-3129366-B1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYNCHRONICITY PHARMA INC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10759777-B2 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | Synchronicity Pharma, Inc. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200239884-A1 | METHODS OF TREATING DIABETES AND/OR PROMOTING SURVIVAL OF PANCREATIC ISLETS AFTER TRANSPLANTATION | UNIV MIAMI (US) | 2020-07-30 | — | — | US | disclosed |
| WO-2006034435-A2 | METHODS AND COMPOSITIONS FOR TREATING GLUCOSE-ASSOCIATED CONDITIONS, METABOLIC SYNDROME, DYSLIPIDEMIAS AND OTHER CONDITIONS | POINT THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063719-A1 | Methods for treating diabetes | POINT THERAPEUTICS, INC. (US) | 2006-03-23 | — | — | US | disclosed |
| WO-2006009533-A1 | ANTI-GLYCATED CD59 ANTIBODIES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20050032128-A1 | Anti-glycated CD59 antibodies and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-02-10 | — | — | US | disclosed |
| US-6835545-B2 | Methods, products and treatments for diabetes | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2004-12-28 | — | — | US | disclosed |
| US-20040219606-A1 | Methods, products and treatments for diabetes | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-11-04 | — | — | US | disclosed |
| US-20040166531-A1 | METHODS, PRODUCTS AND TREATMENTS FOR DIABETES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-08-26 | — | — | US | disclosed |
| EP-1386165-A2 | INFLAMMATORY MARKERS FOR DETECTION AND PREVENTION OF DIABETES MELLITUS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030100486-A1 | Inflammatory markers as tools in the detection and prevention of diabetes mellitus and as tools to aid in the selection of agents to be used for the prevention and treatment of diabetes | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-29 | — | — | US | disclosed |
| WO-2002048715-A2 | INFLAMMATORY MARKERS FOR DETECTION AND PREVENTION OF DIABETES MELLITUS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162333-A1 | GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF | CD59, SIGLEC9, CD209 | ALDH1A1 927/4885LMNA 140/4885AKR1C3 477/4885 |
| US-11891448-B2 | Glycated CD59 peptides, their preparation, and uses thereof | CD59, SIGLEC9, CD209 | ALDH1A1 927/4885LMNA 140/4885AKR1C3 477/4885 |
| US-20210171495-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | ALDH1A1 2882/4885LMNA 1390/4885AKR1C3 230/4885 |
| US-10759777-B2 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | CRY1, CRY2, HCCS | ALDH1A1 2882/4885LMNA 1390/4885AKR1C3 230/4885 |
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | ALDH1A1 2882/4885LMNA 1390/4885AKR1C3 230/4885 |
| US-20060063719-A1 | Methods for treating diabetes | IAPP, SLC5A2, SLC2A3 | ALDH1A1 1611/4885LMNA 1599/4885AKR1C3 1202/4885 |
| US-11161910-B2 | Glycated CD59 peptides, their preparation, and uses thereof | CD59, SIGLEC9, CD209 | ALDH1A1 927/4885LMNA 140/4885AKR1C3 477/4885 |
| US-20240190837-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | ALDH1A1 2882/4885LMNA 1390/4885AKR1C3 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.